Personalis at Immuno-Oncology Summit 2018

Kedar Hastak, PhD
Field Application Scientist
Cancer Genomics & Immuno-Oncology

Thursday, August 30 | 12:15 PM

Overcoming the Obstacles of Neoantigen Detection for Cancer Vaccine Development

Conventional exome assays often have gaps in sequencing coverage, leading to missed neoantigens.  Personalis developed the ACE ImmunoID platform to overcome this and other challenges for more comprehensive neoantigen identification. ACE ImmunoID combines augmented exome/transcriptome assays with state-of-the-art bioinformatics, optimized sample preparation, and automated processes to accelerate personalized cancer vaccine development.

• Key considerations for designing rapid, patient-centric processes for vaccine clinical trial
• ACE ImmunoID technical characteristics and overview of the robust analytical validation
• Comprehensive bioinformatics reporting and review of analytical modules including HLA Typing, Similarity-to-Self, Similarity-to-Known-Antigens, Candidate Neoantigen Ranking, and Tumor Immunogenomics